Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 318

Showing 1-25 of 318 citing articles:

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
The Lancet (2023) Vol. 401, Iss. 10391, pp. 1853-1865
Open Access | Times Cited: 490
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Domenico Alvaro, Gregory J. Gores, Joël Walicki, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 181-208
Open Access | Times Cited: 132
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J. Harding, Jia Fan, Do‐Youn Oh, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. 772-782
Open Access | Times Cited: 126
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 99
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 92
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 2012-2031
Open Access | Times Cited: 69
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
Margherita Rimini, Lorenzo Fornaro, Sara Lonardi, et al.
Liver International (2023) Vol. 43, Iss. 8, pp. 1803-1812
Open Access | Times Cited: 62
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 53
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
Howard A. Burris, Takuji Okusaka, Arndt Vogel, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 5, pp. 626-635
Closed Access | Times Cited: 34
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 16
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque, et al.
ESMO Open (2024) Vol. 9, Iss. 6, pp. 103488-103488
Open Access | Times Cited: 16
Drug Delivery System Targeting Cancer-Associated Fibroblast for Improving Immunotherapy
Zhongsong Zhang, Rong Wang, Long Chen
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 483-503
Open Access | Times Cited: 3
Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers
Xin Wang, Anna Saborowski, Gonzalo Sapisochín, et al.
Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 2
Nanomaterials in cancer immunotherapy: targeting cancer-associated fibroblasts
Zhongsong Zhang, Long Chen
Cancer Nanotechnology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 2
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Qibiao Wu, Haley Ellis, Giulia Siravegna, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 198-208
Open Access | Times Cited: 39
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 36
Clinical development and management of adverse events associated with FGFR inhibitors
Vivek Subbiah, Srđan Verstovšek
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101204-101204
Open Access | Times Cited: 33
Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
Alessio Ardizzone, Valentina Bova, Giovanna Casili, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1002-1002
Open Access | Times Cited: 32
Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Maud B. A. van der Kleij, Niels A.D. Guchelaar, Ron H.J. Mathijssen, et al.
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 10, pp. 1333-1364
Open Access | Times Cited: 31
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma
Julien Caldéraro, Narmin Ghaffari Laleh, Qinghe Zeng, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 30
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 27
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
Marine Valéry, Damien Vasseur, Francesco Fachinetti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4446-4446
Open Access | Times Cited: 27
New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy
Ezequiel Mauro, Joana Ferrer, Tamara Saurí, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1244-1244
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top